Strategies of Protection of Normal Cells During Chemo- and Radio-Therapy Based on Modulation of Cell Cycle and Apoptotic Pathways

摘要: The ultimate goal of cancer therapy is to selectively kill cells, while sparing normal cells. Therefore, major research efforts have been aimed at the discovery molecular targets that are specific for One such target BCR-ABL, a product chromosomal translocation (Philadelphia chromosome), which both and vital chronic myelogenous leukemia (CML). BCR-ABL most validated in oncology (Druker, 2002; Druker Lydon, 2000; Daley, 2003). Gleevec (Imatinib, STI571), an inhibitor c-Kit, demonstrated excellent clinical effectiveness, causing remission more than 90% patients with phase CML (Kantarjian et al., Without doubt, successful treatment -expressing kinase spectacular achievement modern oncology. Unfortunately, this only example. In fact, unique target. Other either non-specific cells or dispensable growth survival. Most drugs affect (e.g. inhibitors histone deacetylases farnesyltransferase) do not (some factor receptors cyclin dependent 2). This CO-incidental. First, almost all anticancer drug present Second, multiple genetic alterations. single receptor may be cell proliferation (Fig. 1,). ,As emphasized by Richard